Camrelizumab + Investigator's choice of Chemotherapy
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma
Trial Timeline
Jul 17, 2020 → Dec 1, 2023
NCT ID
NCT04342936About Camrelizumab + Investigator's choice of Chemotherapy
Camrelizumab + Investigator's choice of Chemotherapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Classical Hodgkin Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04342936. Target conditions include Classical Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04342936 | Phase 3 | UNKNOWN |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 52 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 32 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |
| GEN3017 | Genmab | Phase 1/2 | 38 |